Your browser doesn't support javascript.
loading
Cost-benefit of influenza vaccination in preventing sudden cardiac arrest amongst Australian adults.
Wei, Jenny; Tan, Timothy C; Moa, Aye M; MacIntyre, C Raina.
Afiliación
  • Wei J; Biosecurity Program, Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
  • Tan TC; School of Medical Sciences, UNSW Medicine, The University of New South Wales, Sydney, New South Wales, Australia.
  • Moa AM; Biosecurity Program, Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia. Electronic address: a.moa@unsw.edu.au.
  • MacIntyre CR; Biosecurity Program, Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
Vaccine ; 42(7): 1593-1598, 2024 Mar 07.
Article en En | MEDLINE | ID: mdl-38341292
ABSTRACT

OBJECTIVE:

The objective of the study was to estimate the economic cost benefit of funding influenza vaccination to all Australian adults 50-64 years and predict its effect on sudden cardiac arrest (SCA) deaths and hospitalisation.

METHODS:

We combined SCA hospitalisation data from the Australian Institute of Health and Welfare (AIHW) with survival, vaccination, and cost parameters from published literature to create a model estimating the cost benefit of universally funded influenza vaccinations to prevent SCA deaths and hospitalisation. Costs were considered from a government perspective and included cost of vaccines and GP consultations, whilst averted deaths were estimated through the age-adjusted value of a statistical life.

RESULTS:

The target policy was estimated to prevent 278 SCA hospitalisations and 1269 SCA deaths. This would result in cost-savings of almost $4 billion annually, with an incremental benefit-cost ratio (BCR) of 59.94. The majority of savings were associate with averted deaths. When a sensitivity analysis was performed by altering statistical life year values and reducing life years left, the cost-saving remained significant with a minimum BCR of 29.97 derived.

CONCLUSIONS:

Reducing SCA through extended vaccination including adults 50-64 years is likely to be a cost beneficial policy from a governmental perspective. SCA deaths account for a significant economic loss due to the high mortality rate, which was far greater than the costs saved through averted hospitalisations. More accurate parameters are needed to improve the reliability of these estimate; however, this model can be used as a basis for further research into the economic impact of SCA.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana Tipo de estudio: Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Límite: Adult / Humans País/Región como asunto: Oceania Idioma: En Revista: Vaccine Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana Tipo de estudio: Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Límite: Adult / Humans País/Región como asunto: Oceania Idioma: En Revista: Vaccine Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Países Bajos